Clinical Trials Logo

Clinical Trial Summary

This observational study evaluates prevalence of functional perinea disorders (stress urinary incontinence, overactive bladder syndrome, dysuria, anal incontinence) on CF adults patients of the North-West CF Network. Its aims are to measure the severity of urinary and anorectal symptoms ; assess their impact on patients' quality of life, sexuality, care and social life and relationships ; identify the medical and demographic factors associated with the severity of urinary and anorectal disorders and their impact and determine the relationship between the severity of these disorders, various repercussions, and risk factors.


Clinical Trial Description

Urine and/or anal leakage are more frequent and troublesome for CF patients: leaks occur during efforts or laugh like in other people, but also when coughing or sneezing, which are amplified during periods of exacerbation and with the degradation of the pulmonary condition. In addition, fear of leakage can disrupt medical care: discomfort during physiotherapy, pulmonary function test. Urinary and anorectal functional disorders are therefore not only a factor degrading the quality of life but also a risk factor for worsening bronchial obstruction, patients limiting their cough and / or their care to avoid episodes of leakage. Given the lack literature data, investigators wanted to explore these areas.

Validated and specific questionnaires will be self and anonymously administered to adult patients (n=175). The time requested to fill the forms is estimated to 1H. Questionnaires about sexual health are optional.

Prospects considered, depending on the results, are:

- Extension to the adolescent population (14 and over);

- National extension;

- Systematic proposal of a screening and an appropriate management of pelvic floor functional disorders, depending on influent characteristics (age, gender ...): multidisciplinary working group to develop guidelines and specific tools for professional training and / or patient education;

- Implementation of a comparative study of interventions. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02894619
Study type Observational
Source Fondation Ildys
Contact Laetitia Gueganton, PhD
Phone 33298293448
Email laetitia.gueganton@ildys.org
Status Not yet recruiting
Phase N/A
Start date September 2016
Completion date May 2017

See also
  Status Clinical Trial Phase
Terminated NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Completed NCT02449785 - Assessment of Cystic Fibrosis Lung Involvement With UTE Pulse Sequences N/A
Terminated NCT02170025 - Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients Phase 2
Completed NCT02465450 - Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis Phase 2
Recruiting NCT03335202 - Longitudinal Analysis of Respiratory and Intestinal Microbiome in Cystic Fibrosis N/A
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Completed NCT00903201 - 28 Day Repeat Dose in Cystic Fibrosis Patients Phase 2
Recruiting NCT03181932 - A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients Phase 3
Not yet recruiting NCT03617718 - Project 2 Airway Potential Hydrogen (pH) in Asthma Phase 1/Phase 2
Not yet recruiting NCT02748798 - Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders Early Phase 1
Active, not recruiting NCT02721498 - Improving Outcome Measures For Adult CF ACT Trials N/A
Active, not recruiting NCT02730208 - A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation Phase 2
Completed NCT02823964 - EASY: Extended Access to Sollpura Over Years Phase 4
Completed NCT02875366 - A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Phase 4
Completed NCT02504827 - Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis Phase 4
Completed NCT02564354 - Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation Phase 1
Completed NCT02421120 - Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Phase 4
Recruiting NCT02225899 - BioEnergetics and Metabolomics in Cystic Fibrosis
Recruiting NCT02907788 - Inflammatory Markers in Broncho-alveolar Lavage Fluid as Risk Factors for Lung Disease in Infants With Cystic Fibrosis: the I-BALL Study N/A
Completed NCT02212587 - Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex Phase 1